ACADIA Pharmaceuticals Inc. (ACAD)

Company Overview

Acadia Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. Its products include ACP-103, which is in Phase III clinical trials for the treatment of Parkinson’s disease psychosis, and in Phase II clinical trials for the treatment of schizophrenia and sleep maintenance insomnia. The company’s products also comprise ACP-104, a Phase II clinical trial product for the treatment of schizophrenia; and AGN-XX and AGN-YY, which are in Phase II clinical trials for the treatment of neuropathic pain in collaboration with A...

read more


To see the headquarters in Google Street View &trade, drag this yellow guy: over to the red pointer:

Contact Information:

Business Address: 3911 Sorrento Valley Boulevard, San Diego, CA 92121, United States
Mailing Address: -
Phone: 858-558-2871
Fax: 858-558-2872
Website: http//

Company Details:

Symbol: ACAD
SIC: 2834
State location: CA
Sector: -
State of Inc: DE
Employees: 27
Type: -

Key executives:

Name Age Position
Bo-Ragnar Tolf Ph.D. 69 VP of Chemistry and Managing Director of ACADIA Pharmaceuticals A/S
Brian Lundstrom 58 Sr. VP of Bus. Devel.
Roger G. Mills M.D. 2020 Exec. VP of Devel.
Thomas H. Aasen CPA. 59 Chief Financial Officer, Principal Accounting Officer, VP, Sec. and Treasurer
Uli Hacksell Ph.D. 70 Chief Exec. Officer